This book summarises the available evidence on the comparative efficacy, effectiveness, and harms of 12 second-generation antidepressants: bupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, nefazodone, paroxetine, sertraline, trazodone and venlafaxine in treating patients with MDD, dysthymia and subsyndromal depression. It also evaluates the comparative efficacy and effectiveness for maintaining remission and for treating accompanying symptoms such as anxiety, insomnia or neurovegetative symptoms..